Optimal sampling times in population pharmacokinetic studies
We propose a simulation-based approach to decision theoretic Bayesian optimal design. The underlying probability model is a population pharmacokinetic model which allows for correlated responses (drug concentrations) and patient-to-patient heterogeneity. We consider the problem of choosing sampling times for the anticancer agent paclitaxel, using criteria related to the total area under the curve, the time above a critical threshold and the sampling cost.
No Supplementary Data
No Article Media